346 related articles for article (PubMed ID: 29991141)
1. Parkinson's Disease and Melanoma: Co-Occurrence and Mechanisms.
Bose A; Petsko GA; Eliezer D
J Parkinsons Dis; 2018; 8(3):385-398. PubMed ID: 29991141
[TBL] [Abstract][Full Text] [Related]
2. Melanin and Neuromelanin: Linking Skin Pigmentation and Parkinson's Disease.
Krainc T; Monje MHG; Kinsinger M; Bustos BI; Lubbe SJ
Mov Disord; 2023 Feb; 38(2):185-195. PubMed ID: 36350228
[TBL] [Abstract][Full Text] [Related]
3. Pigmentation genes link Parkinson's disease to melanoma, opening a window on both etiologies.
Herrero Hernández E
Med Hypotheses; 2009 Mar; 72(3):280-4. PubMed ID: 19027242
[TBL] [Abstract][Full Text] [Related]
4. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
5. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
6. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
[TBL] [Abstract][Full Text] [Related]
7. Melanin and Neuromelanin Fluorescence Studies Focusing on Parkinson's Disease and Its Inherent Risk for Melanoma.
Leupold D; Szyc L; Stankovic G; Strobel S; Völker HU; Fleck U; Müller T; Scholz M; Riederer P; Monoranu CM
Cells; 2019 Jun; 8(6):. PubMed ID: 31208049
[TBL] [Abstract][Full Text] [Related]
8. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
9. The association between Parkinson's disease and melanoma.
Pan T; Li X; Jankovic J
Int J Cancer; 2011 May; 128(10):2251-60. PubMed ID: 21207412
[TBL] [Abstract][Full Text] [Related]
10. Parkinson's Disease, Melanoma, and Keratinocyte Carcinoma: A Population-Based Study.
Lerman S; Amichai B; Weinstein G; Shalev V; Chodick G
Neuroepidemiology; 2018; 50(3-4):168-173. PubMed ID: 29566384
[TBL] [Abstract][Full Text] [Related]
11. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
12. Regional analysis and genetic association of nigrostriatal degeneration in Lewy body disease.
Kasanuki K; Heckman MG; Diehl NN; Murray ME; Koga S; Soto A; Ross OA; Dickson DW
Mov Disord; 2017 Nov; 32(11):1584-1593. PubMed ID: 28949048
[TBL] [Abstract][Full Text] [Related]
13. The particular relationship between Parkinson's disease and malignancy: a focus on skin cancers.
Inzelberg R; Israeli-Korn SD
J Neural Transm (Vienna); 2009 Nov; 116(11):1503-7. PubMed ID: 19789839
[TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease and cancer: insights for pathogenesis from epidemiology .
D'Amelio M; Ragonese P; Sconzo G; Aridon P; Savettieri G
Ann N Y Acad Sci; 2009 Feb; 1155():324-34. PubMed ID: 19250224
[TBL] [Abstract][Full Text] [Related]
15. Skin cancer and Parkinson's disease.
Ferreira JJ; Neutel D; Mestre T; Coelho M; Rosa MM; Rascol O; Sampaio C
Mov Disord; 2010 Jan; 25(2):139-48. PubMed ID: 20063399
[TBL] [Abstract][Full Text] [Related]
16. PARKIN Inactivation Links Parkinson's Disease to Melanoma.
Hu HH; Kannengiesser C; Lesage S; André J; Mourah S; Michel L; Descamps V; Basset-Seguin N; Bagot M; Bensussan A; Lebbé C; Deschamps L; Saiag P; Leccia MT; Bressac-de-Paillerets B; Tsalamlal A; Kumar R; Klebe S; Grandchamp B; Andrieu-Abadie N; Thomas L; Brice A; Dumaz N; Soufir N
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26683220
[TBL] [Abstract][Full Text] [Related]
17. Neuronal vulnerability in Parkinson's disease.
Double KL
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?
Ling H; Kearney S; Yip HL; Silveira-Moriyama L; Revesz T; Holton JL; Strand C; Davey K; Mok KY; Polke JM; Lees AJ
J Neurol Neurosurg Psychiatry; 2016 Jun; 87(6):633-41. PubMed ID: 26209716
[TBL] [Abstract][Full Text] [Related]
19. Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature.
Zanetti R; Loria D; Rosso S
Melanoma Res; 2006 Jun; 16(3):201-6. PubMed ID: 16718266
[TBL] [Abstract][Full Text] [Related]
20. Classic and evolving animal models in Parkinson's disease.
Pingale T; Gupta GL
Pharmacol Biochem Behav; 2020 Dec; 199():173060. PubMed ID: 33091373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
